Mahana Therapeutics Earns CE Mark for Digital Irritable Bowel Syndrome Therapeutic
Mahana Therapeutics has been given CE mark certification for Parallel, its digital therapeutic for reducing the severity of irritable bowel syndrome (IBS) symptoms.
The prescription-only therapeutic is a three-month digital program that helps patients change certain behaviors that can worsen IBS symptoms. It has been proven in clinical trials to reduce symptom severity, the company said.
Mahana’s IBS therapeutic is also cleared by the FDA and it received a recommendation from the UK’s National Institute for Health and Care Excellence (NICE) for use by the National Health Service.